MYADM and pulmonary arterial hypertension: Compared with the control virus-treated rats, those infected with Ad-miR-182-3p-inhibitor or injected with MCT exhibited increased Myadm expression (Figure 2A-B), an increased pulmonary hypertension pulmonary systolic blood pressure (PASP, Figure 2C), increased right ventricular systolic pressure (RVSP, Figure 2D), decreased tricuspid annular displacement (TAPSE, p=0.07, Figure S1A), and decreased maximum pulmonary velocity (PVmax, Figure S1B).